CLINICAL OUTCOME OF VERY REFRACTORY HODGKIN'S LYMPHOMA

被引：0
|
作者：
Gaudio, F. [1 ]
Laddaga, F. E. [1 ]
Laddaga, F. E. [1 ]
Perrone, T. [1 ]
Perrone, T. [1 ]
Pinto, P. [1 ]
Leo, M. [1 ]
Bitetto, C. [1 ]
De Candia, M. S. [1 ]
Ingravallo, G. [2 ]
Pedote, P. [3 ]
Pastore, D. [1 ]
Specchia, G. [1 ]
机构：
[1] Univ Bari, Hematol, Bari, Italy
[2] Univ Bari, Patol, Bari, Italy
[3] Univ Bari, Radiol, Bari, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1776
引用
收藏
页码：704 / 704
页数：1
相关论文
共 50 条
  • [21] Advances in the Treatment of Relapsed or Refractory Hodgkin's Lymphoma
    Ramchandren, Radhakrishnan
    ONCOLOGIST, 2012, 17 (03): : 367 - 376
  • [22] A new option for relapsed or refractory Hodgkin's lymphoma
    Sharma, Sharan Prakash
    LANCET ONCOLOGY, 2012, 13 (05): : E192 - E192
  • [23] Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma
    Chen, Runzhe
    Chen, Baoan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1729 - 1733
  • [24] Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma
    Mendler, J. H.
    Kelly, J.
    Voci, S.
    Marquis, D.
    Rich, L.
    Rossi, R. M.
    Bernstein, S. H.
    Jordan, C. T.
    Liesveld, J.
    Fisher, R. I.
    Friedberg, J. W.
    ANNALS OF ONCOLOGY, 2008, 19 (10) : 1759 - 1764
  • [25] New treatment for relapsed or refractory Hodgkin's lymphoma
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2019, 20 (06): : E298 - E298
  • [26] Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
    Fedele, Roberta
    Martino, Massimo
    Recchia, Anna Grazia
    Irrera, Giuseppe
    Gentile, Massimo
    Morabito, Fortunato
    JOURNAL OF IMMUNOLOGY RESEARCH, 2015, 2015
  • [27] Non-Hodgkin's lymphoma in very elderly patients over 80 years.: A descriptive analysis of clinical presentation and outcome
    Thieblemont, C.
    Grossoeuvre, A.
    Houot, R.
    Broussais-Guillaumont, F.
    Salles, G.
    Traulle, C.
    Espinouse, D.
    Coiffier, B.
    ANNALS OF ONCOLOGY, 2008, 19 (04) : 774 - 779
  • [28] Clinical outcome and prognostic factors evaluation in adolescent patients with relapsed or refractory Hodgkin's lymphoma receiving autologous stem cell transplant
    Akhtar, Saad
    El Weshi, Amr
    Rahal, Mohemed
    Abdelsalam, Mahmoud
    Janabi, Iman
    Hamed, Husseini
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 425 - 425
  • [29] COMPLETE RESPONSE TO IGEV (IFOSFAMIDE, GEMCITABINE AND VINORELBINE) AND OUTCOME IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA PATIENTS
    Anastasia, A.
    Mazza, R.
    Giordano, L.
    Balzarotti, M.
    Magagnoli, M.
    Castagna, L.
    Spina, M.
    Tirelli, U.
    Santoro, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 37 - 37
  • [30] Outcome of autologous hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory Hodgkin's lymphoma
    Hazar, Volkan
    Kesik, Vural
    Aksoylar, Serap
    Karakukcu, Musa
    Ozturk, Gulyuz
    Kupesiz, Alphan
    Atas, Erman
    Oniz, Haldun
    Kansoy, Savas
    Unal, Ekrem
    Tanyeli, Atila
    Erbey, Fatih
    Elli, Murat
    Tacyildiz, Nurdan
    Karasu, Gulsun Tezcan
    Kocak, Ulker
    Anak, Sema
    Bengoa, Sebnem Yilmaz
    Sezgin, Gulay
    Atay, Didem
    Unal, Emel
    Uygun, Vedat
    Kurucu, Nilgun
    Kaya, Zuhre
    Yesilipek, Akif
    PEDIATRIC TRANSPLANTATION, 2015, 19 (07) : 745 - 752
12345